FISCAL YEAR 2016 ADOPTED BUDGET-IN-BRIEF

whitePaper | June 30, 2020

There’s no arguing that preventing failures and accidents is critical for industry. Unexpected incidents can grind operations to a halt for extended periods of time and necessitate expensive repairs. For example, just 12 hours of downtime for an oil production platform could cost six to eight million dollars in lost production opportunity alone. A single day of grounding for a plane costs roughly four to five million dollars. Because of these disruptions, industrial sectors are always on the lookout for newer, better maintenance methods, and the approach on everyone’s lips right now is predictive maintenance.

whitePaper | March 24, 2023

Workday Government Cloud offers U.S. federal agencies a world-class portfolio of financial management and human capital management cloud applications running in an environment with a FedRAMP Moderate authorization. Workday Government Cloud enables organizations to effectively and securely manage their demanding workforce, finance, and mission processes while helping to meet new Zero Trust Architecture (ZTA) strategy mandates

whitePaper | December 7, 2022

FedRAMP was created so that the US government can use the cloud while still protecting systems and data. FedRAMP helps provide clarity for both government agencies and cloud providers so that each knows what is required for cloud use. If you’re a cloud service provider or a government agency wanting to use the cloud, you must demonstrate that you can meet FedRAMP compliance requirements.

whitePaper | September 19, 2022

Sophos' annual study of the real-world ransomware experiences of IT professionals in the state and local government sector has revealed an ever more challenging attack environment. Together with the growing financial and operational burden ransomware places on its victims, it also shines new light on the relationship between ransomware and cyber insurance - including how insurance drives changes to cyber defenses.

whitePaper | February 12, 2020

Both the U.S. Government and biopharmaceutical industry have been central engines for developing new medical treatments and cures, thereby lowering the effective price of better health for patients worldwide. The sector has done so by being both the world leader in these biopharmaceutical cures and treatments as well as the source of the returns that are required to fund new medical R&D investments.

whitePaper | December 10, 2019

The Trump administration, members of Congress from both parties, and many states have introduced proposals to combat high drug prices. Too often missing from these reform efforts, however, is a clear understanding of a root cause of the crisis: the suppression of fair market competition through various forms of monopoly. This white paper examines and proposes solutions for the two main ways that monopoly drives up the costs and lowers the quality of prescription drugs: increasing corporate concentration in the pharmaceutical industry, and the monopoly markets for individual drugs created by a deeply flawed and increasingly abused patent and regulatory system.